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Abstract
There is great concern regarding the rapid emergence and spread of drug-resistance in
Plasmodium falciparum, the parasite responsible for the most severe form of human
malaria. Parasite populations resistant to some or all the currently available antimalarial
treatments are present in different world regions. Considering the need for novel and inte-
grated approaches to control malaria, combinations of drugs were tested on P. falciparum.
The primary focus was on doxycycline, an antibiotic that specifically targets the apicoplast of
the parasite. In combination with doxycycline, three different drugs known to inhibit efflux
pumps (verapamil, elacridar and ivermectin) were tested, with the assumption that they
could increase the intracellular concentration of the antibiotic and consequently its efficacy
against P. falciparum. We emphasize that elacridar is a third-generation ABC transporters
inhibitor, never tested before on malaria parasites. In vitro experiments were performed on
asexual stages of two strains of P. falciparum, chloroquine-sensitive (D10) and chloroquine-
resistant (W2). Incubation times on asynchronous or synchronous cultures were 72h or 96h,
respectively. The antiplasmodial effect (i.e. the IC50) was determined by measuring the
activity of the parasite lactate dehydrogenase, while the interaction between drugs was
determined through combination index (CI) analyses. Elacridar achieved an IC50 concentra-
tion comparable to that of ivermectin, approx. 10-fold lower than that of verapamil, the other
tested ABC transporter inhibitor. CI results showed synergistic effect of verapamil plus doxy-
cycline, which is coherent with the starting hypothesis, i.e. that ABC transporters represent
potential targets, worth of further investigations, towards the development of companion
molecules useful to enhance the efficacy of antimalarial drugs. At the same time, the
observed antagonistic effect of doxycycline in combination with ivermectin or elacridar
highlighted the importance of drug testing, to avoid the de-facto generation of a sub-dosage,
a condition that facilitates the development of drug resistance.
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Introduction
Despite the efforts to eradicate malaria, the disease is still one of the major causes of death in
low-income countries, with over 200 million cases in 2018, and about half a million deaths. In
the last few years, the trend of malaria decrease has levelled off, with a slight although worri-
some increase in malaria cases in the period 2015–2017 [1]. This recent increase in malaria
incidence can be attributed to many social and economic factors, but also to the development
of multiple resistances of the parasites to antimalarial drugs [2, 3], and of the vectors towards
insecticides [4, 5]. Plasmodium falciparum has developed resistance to all the currently avail-
able antimalarial drugs [6]. The factors that influence the emergence and spread of resistance
are not completely known, but drug pressure is likely a key element for the selection of resis-
tant parasite mutants [7].
Combined drug therapies, i.e. the association of different drugs with different mechanisms
of action and pharmacokinetics, are proving to be more effective for malaria control than
monotherapy [8] and have been introduced also with the intent to delay the onset of resistance.
Since 2001, WHO recommends artemisinin-based combination therapies (ACTs) as first-line
intervention in almost all countries where malaria is endemic [9], but resistance to ACT is also
emerging [10]. Thus, the armamentarium of effective antimalarials is quite limited, and the
search for novel companion drugs to be used in antimalarial combination therapy is a critical
need.
In the area of malaria research, the apicoplast has attracted a great deal of attention, also for
its potential as a target for novel therapeutic molecules [11]. The apicoplast is a cellular organ-
elle, present in Apicomplexa parasites, including Plasmodium spp. It is considered as a relic of
a chloroplast, with no photosynthetic ability [12], but indispensable for the survival of the par-
asite [13]. The prokaryotic-like metabolic pathways of the apicoplast make it susceptible to sev-
eral antibacterial drugs [14]. Doxycycline has been shown to specifically target the apicoplast
in Plasmodium spp., determining an anti-parasite effect [15]. The antimalarial effects of doxy-
cycline are however limited, mainly due to its delayed effect, and the combinations with other
drugs are recommended for the use of this antibiotic in malaria control [16].
A strategy that has been proposed to increase the efficacy of antibiotic treatments targeting
cellular organelles, intracellular symbionts or pathogenic bacteria is to combine antibiotics
with inhibitors of drug efflux pumps [17], such as the ABC transporters. The inhibition of
these efflux pumps is expected to increase drug concentration into target cells, organelles and
intracellular bacteria [18]. Verapamil is a first generation, widely investigated inhibitor of ABC
efflux pumps. Verapamil has already been tested on P. falciparum [19, 20], but not with the
drug combination tested here. Elacridar (GF120918) is a potent, third-generation ABC trans-
porters inhibitor, with a reported ability in blocking efflux pumps of different cell lines in
vitro, 100-fold more potent than verapamil (i.e. with the same efficacy of verapamil at 100-fold
lower concentrations) [21, 22]. There are no published papers on the effect of elacridar on
malaria parasites. A study has however been published on another apicomplexan, Toxoplasma
gondii, where elacridar was shown to severely inhibit parasite cell invasion and multiplication
[23].
Surprisingly, ivermectin, a macrocyclic lactone widely used in antiparasitic chemotherapy,
has also been proposed as an inhibitor of drug efflux pumps [24], and shown to act synergisti-
cally with doxycycline in the anti-symbiotic chemotherapy of dog filariases [17]. This drug
could thus be investigated as a further potential inhibitor of drug efflux pumps, to be used in
combination with doxycycline in antimalarial treatment. On the other hand, doxycycline has
been shown to increase the intracellular concentration of macrocyclic lactones, which makes
the combination treatment ivermectin-doxycycline worth of further investigation [25].
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Ivermectin is used in mass therapy in tropical countries for the control of river blindness, in
regions in which both the filarial nematode Onchocerca volvulus and malaria are endemic.
Recent papers have shown that the feeding of mosquitoes on humans treated with ivermectin
causes detrimental effects on Anopheles mosquitoes, with a reduction of population densities
[26, 27]. Moreover, several studies have shown evidences for a reduction in malaria transmis-
sion due to the administration of ivermectin [28]. Thus, it has been recommended an intensifi-
cation of mass administration of ivermectin, since this could lead not only to the control of
onchocerciasis but could also contribute to malaria control, through the reduction of vector
populations [29]. However, mass administration of ivermectin in malaria-endemic countries
implies that a part of the population is temporally exposed at both ivermectin and antimalarial
drugs [30]. Thus, should ivermectin interact in an antagonistic way with one or more antima-
larial drugs, this could have a negative impact on the control of both filariasis and malaria,
with a reduction in efficacy of the treatments and an increase in resistance development.
Based on the above background information, with the goal of investigating novel combina-
tions of molecules that could be detrimental to malaria parasites, this study was focussed on a
molecule that targets the apicoplast, doxycycline, on two inhibitors of ABC efflux pumps,
verapamil and elacridar, and on ivermectin, a drug that is both interesting as a potential efflux
pump inhibitor, as well as it is at the core of parasite control programmes in tropical medicine.




Reagents for parasite maintenance and for the assays were purchased from different suppliers:
RPMI 1640 medium (GIBCO BRL), AlbuMax II (Invitrogen), hypoxanthine (Sigma-Aldrich),
HEPES and L-glutamine (EuroClone). All drugs (elacridar, verapamil, ivermectin, and doxy-
cycline) were purchased from Sigma-Aldrich, maintained in DMSO and diluted for the tests
with the culture medium prior to the experiments.
Parasites and drug susceptibility testing
All the combinations of drugs were tested against two laboratory adapted strains of P. falcipa-
rum: the P. falciparum clone D10 (from Papua New Guinea, chloroquine susceptible) origi-
nally obtained from Prof P. Smith (Div. Clinical Pharmacology, University of Cape Town, SA)
and the P. falciparum Indochina III/CDC, clone W2 (chloroquine resistant) originally
obtained from the Walter Reed Army Institute of Research, Washington, DC. Both parasite
strains were maintained in continuous cultures by a modification of the methods of Trager
and Jensen [31]. Each culture was maintained at 5% haematocrit (human type A+ red blood
cells [RBC]) in RPMI 1640 medium supplemented with 1% AlbuMax II (lipid-rich bovine
serum albumin), 0,5 mM hypoxanthine, 20 mM HEPES, and 2 mM L-glutamine, in a standard
gas mixture consisting of 94% N2, 5% CO2, and 1% O2 at 37˚C. RBC were obtained from the
AVIS Comunale Milano (www. https://avismi.it) with the written consent of anonymous
healthy donors, following the EU Directive 2004/23/EC, 2002/98/EC and the Directive (Suppl.
Ord. "G.U n. 300 del 28 dicembre 2015) from the Italian Ministry of Health, on human cells,
tissues, blood and blood components.
Synchronization of the parasite, for the experiments with an incubation time corresponding
to the duration of 2 asexual cycles, was performed according to published protocols [32].
Parasite susceptibility testing was done with the colorimetric assay of LDH (lactate dehy-
drogenase) [33]. All the combinations were tested with incubation times of 72h, on
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asynchronous cultures of the parasites, and 96h, on synchronized cultures of the parasites (late
ring stage, approximately 24h post invasion as suggested by Dahl et al. [15]). For the combina-
tion test, serial dilutions of the first drug (usually doxycycline) were done directly in a 96 flat
bottom well plate. The starting concentration (for serial dilutions) was assigned so that the
50% inhibitory concentration (IC50) of each drug would be in the centre of the plate. After
that, selected dilutions of the second drug were added to the first one. Treatments with two
combined drugs were performed by keeping one drug at fixed concentration(s) while varying
the other (selected drug concentrations are reported in the S2 Text). The cultures of parasites
were diluted to a final haematocrit of 1% and a final parasitaemia of 1% (or 0,2% at ring stage
for 96h incubation time) and placed in a 96 wells plate with the drugs. Each combination of
concentrations of the drugs was plated in duplicate, with a triplicate blank sample (only RBC)
and a triplicate of negative control (only parasites). The IC50 values were determined for each
drug alone and for the drugs in combination, directly by the Synergy4-BioTek reader.
The 96-well plates with the suspensions of the drugs and parasites were incubated at 37˚C
for 72h or 96h. All the combination experiments were performed three independent times.
For the experiments with 96h incubation times, the culture medium has been changed after
24h for the nutrient needs of the parasites. Assays with medium change at different points (48
or 72h –results not shown) were also performed, but the results were similar to the experi-
ments with a change of the media at 24h of incubation. Thus, for more practical scheduling of
the experiments, all the tests were done with the change at 24h of incubation.
Data analyses
Statistical analysis was performed on the values of IC50 to compare the effect of drugs against
the two strains of P. falciparum with the two incubation times. The data were analysed using
GraphPad Prism 5 utilizing the analysis of variance (two ways ANOVA) followed by Sidak
multiple comparisons test (P-values <0.05 have been considered significant).
The synergism, additivity and antagonism of the combination drug treatment were evalu-
ated using the Chou–Talalay combination index method as implemented in the CompuSyn
software (CompuSyn Inc., Paramus, NJ) [34, 35, 36]. Combination index (CI) values were cal-
culated using the equation:
CI ¼ CA;x=ICx;A þ CB;x=ICx;B
where ICx,A and Cx,B are the concentrations of drug A and drug B used as a single agent to pro-
duce a given effect x and CA,x and CB,x are the concentrations of drug A and drug B in the com-
bination to produce that same effect. A Fa-CI plot for each drug combination (Chou-Talalay
plots), with CI on y- axis as a function of effect level (fa) on the x- axis, were generated and
used to interpret drug combination effects [34, 35]. Synergism, additivity or antagonism were
classified on the basis of the CI values and represented using the recommended symbols in
CompuSyn and CalcuSyn manual [35].
Results
Three different drugs known to inhibit efflux pumps (ivermectin, verapamil, and elacridar)
were tested alone or in combination with doxycycline, with the assumption that this could
determine an increased intracellular concentration of the antibiotic, thus an increased, and
possibly synergistic, effect against P. falciparum. In addition, the combination of verapamil
and ivermectin was also tested.
All the combinations involving doxycycline have been tested with two different incubation
times: 72h, on asynchronous cultures of the parasite, and 96h, on synchronous cultures. These
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two incubation times allowed to observe the effects of the drugs, alone and in combination, on
the parasite viability after one complete asexual cycle (72h assay), or after two complete asexual
cycles (96h assay). The latter time point was included to determine the effect of doxycycline on
parasite viability, which has been reported to be delayed [15].
In a first set of experiments, the IC50 of the compounds alone on both D10 and W2 strains of
P. falciparum were determined. The results are shown in Fig 1 and in S1 Table. After 72h of
incubation, no significant differences were found between the two strains of P. falciparum in
terms of susceptibility to ivermectin, doxycycline or elacridar (Fig 1A–1C). On the contrary the
susceptibility to verapamil was significantly different between the two strains, with a higher
effect on the W2 strain with a 72h incubation (p = 0.0233; Fig 1D). After 96h, namely two para-
site growth cycles, the susceptibility of both strains to ivermectin did not change significantly
(Fig 1A), whereas the IC50 of doxycycline decreased more than 7-folds (p< 0.0001 for both
strains; Fig 1B). The response to elacridar was similar to that to ivermectin, with the D10 strain
being more susceptible than W2 at 96h to both compounds, but the difference was significant
only for elacridar (p = 0.0309; Fig 1C). After 96h, verapamil confirmed its strongest activity
against W2 than against D10 (p = 0.0254; Fig 1D), an activity that was already evident after 72h.
Next, the effects of the combinations of the compounds under study on P. falciparum viabil-
ity were assessed, analysing the results with the Chou-Talalay combination index (CI) method
[34, 35]. The results of these analyses are shown in graphical form in Figs 2 and 3; the data
Fig 1. Graphs showing the IC50 ± Standard Error of each drug alone on P. falciparum chloroquine-sensitive (D10)
or chloroquine-resistant (W2) strains at 72h or 96h time length bioassays. (A) Ivermectin (Ivm); (B) Doxycycline
(Dox); (C) Elacridar (Elc); (D) Verapamil (Vpl). � represents a statistically significative difference between the IC50
values (� p<0.05; �� p<0.01; ���� p<0.0001).
https://doi.org/10.1371/journal.pone.0232171.g001
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recorded after the assays and the CI values are reported in S1 Text; the rankings in terms of the
different degrees of synergism or antagonism, effected based on the CI values, are reported in
S2 Text (rankings in this table are according to the CompuSyn and CalcuSyn manual, with the
+ symbols indicating synergism, and the–antagonism [35]). In Figs 2 and 3, the horizontal line
at y = 1 indicates additivity; CI values below this line indicate synergism, while those above
indicate antagonism. As observed in Fig 2 (as well as in S2 Text), the combination verapamil
plus doxycycline showed a synergistic effect on W2 strain, at both time points. Most of the
other combinations led to antagonistic interactions (e.g. ivermectin and doxycycline; elacridar
and doxycycline). In a few cases CI values scattered around the additivity line were observed
(Figs 2 and 3), with a balance of + and–symbols in the CI ranking table (S2 Text); in other
words, no clear trend was observed toward the antagonistic or the synergistic sides.
Fig 2. Combination index plots for the anti-P. falciparum activity of ivermectin (Ivm), verapamil (Vpl) or elacridar (Elc) in combination with doxycycline
(Dox) against P. falciparum. The data are representative of three independent experiments in duplicate for each combination. The 72h assays were performed on
asynchronous cultures of P. falciparum, while the 96h assays were performed on synchronous cultures of the parasites with a medium change after 24h (see M&M for
details). Combination of Ivm-Dox (from A to D); combination of Vpl-Dox (from E to H); combination of Elc-Dox (From I to L).
https://doi.org/10.1371/journal.pone.0232171.g002
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Discussion
In the assays using single drugs, no significant differences were observed between the CQ-
resistant (W2) and CQ-sensitive (D10) strains of P. falciparum, when incubated for 72h with
the presence of ivermectin, doxycycline or elacridar, meaning that the phenotype associated
with chloroquine resistance has probably no effect on the efficacy of these drugs, at least in the
conditions of the assays (Fig 1A–1C). On the contrary, W2 strain was significantly more sus-
ceptible to verapamil respect to D10 strain (Fig 1D). These results are comparable to those
obtained by Martin et al. [20] with also very similar values of IC50 for verapamil alone on W2
and D6 strains (D6 is a CQ sensitive strain). It is also clear that the efficacy of verapamil against
the parasite is 10-fold lower than that of ivermectin and elacridar at 72h incubation for the sen-
sitive strain D10.
The results obtained for doxycycline were comparable to the ones obtained by Dahl et al.
[15]. The almost 10-fold decrease in IC50 values from 72h to 96h incubation for both strains
(Fig 1A) confirms that the principal effect of the antibiotic against the parasite is delayed, inde-
pendently from the tested strain.
For ivermectin, the results obtained in this study show IC50 values that are different from
those recorded in the few studies so far published. A study tested ivermectin in vitro against
K1 strain of P. falciparum and found an IC50 value of ~9 μM [37], while another study tested it
on different strains of P. falciparum (3D7 and JH26, CQ sensitive; Dd2, K1, JH1, and JH13,
CQ resistant) and obtained IC50 values ranging from 20 to 365 nM [38]. No data are available
in the literature for the in vitro ivermectin IC50 values on the strains tested in this study, nor
for the delayed effect after 96h. As suggested by Pessanha de Carvalho et al. [38], the differ-
ences in IC50 values recorded in different studies might be due to different methodologies, dif-
ferent parasitaemia conditions, and obviously, as in this case, to the use of different strains.
IC50 values for verapamil were comparable to the ones in the literatures for 72h incubation
[20]. No data are available for an incubation of 96h. Since this was the first time that elacridar
was tested on P. falciparum, no data on this parasite are available for this drug in the literature,
for a comparison with our results. Interestingly, the D10 strain of the parasite resulted more
susceptible to both ivermectin and elacridar than the W2 strain, but only after 96h, opposite to
the effect of verapamil.
Fig 3. Combination Index plots for the anti-P. falciparum activity of Ivermectin (Ivm) in combination with Verapamil
(Vpl) with an incubation time of 72h on asynchronous cultures of D10 (A) or W2 (B) strains. The data are
representative of three independent experiments in duplicate for each combination.
https://doi.org/10.1371/journal.pone.0232171.g003
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As for drug combinations and CI analysis, doxycycline in combination with ivermectin
acted in an antagonistic way for both strains. The antagonistic effect was more pronounced
with 72h of incubation (Fig 2A–2B). These results may indicate that ivermectin does not target
the transporters involved in the detoxification of doxycycline in the parasite.
The second efflux pump inhibitor tested in combination with doxycycline was verapamil.
Current evidences suggest that the main target of this inhibitor in the parasite is the efflux
pump of the digestive vacuole of P. falciparum (PfCRT). It is commonly held that only in resis-
tant strains (such as W2), PfCRT effectively transports chloroquine out of the food vacuole;
inhibition of this transporter, e.g. through verapamil, could thus be expected to restore drug
sensitivity in resistant strains [20, 39]. Should PfCRT, either mutated for CQ resistance or not,
be involved in the resistance to doxycycline, the verapamil assays on the two strains would end
with comparable results (i.e. increased sensitivity to doxycycline when combined with verapa-
mil). However, the results of the assays, at 72h, were rather different in the two strains: in D10
the effect of the combination was antagonistic, while in W2 was synergistic. The results at 96h
showed variable results for D10, with synergism at low dosage of doxycycline, and antagonism
at high dosages. In W2, the effect was strongly synergistic for most dosages. Besides the possi-
ble role of PfCRT, overall these results suggest that detoxification of doxycycline involves, at
least in W2 strain, a mechanism that is inhibited by verapamil.
Based on these results, which indicate that the inhibition of drug efflux pumps might
increase the efficacy of antimalarial drugs like doxycycline, elacridar, a third-generation ABC
transporter inhibitor, was tested. The results from the elacridar plus doxycycline combination,
with an incubation of 72h, showed an antagonistic effect for the D10 strains, and an additive
one for W2. With an incubation time of 96h, the effect was antagonistic for both strains, with a
less marked antagonism for D10. The results obtained thus suggest that elacridar and verapa-
mil have different targets in P. falciparum.
The combination of verapamil plus ivermectin was also tested. Indeed, a potentiation of the
effects of ivermectin by verapamil has been reported in several studies on metazoan parasites,
such as nematodes, like Caenorhabditis elegans [40], Haemonchus contortus [41], and Hae-
monchus placei [42], as well as mosquitoes, like Culex pipiens [43]. Taken together, these evi-
dences suggest that the action of verapamil, as an inhibitor of drug-detoxification, is conserved
among distantly related organisms. However, our assays did not reveal any particular trend in
the interaction between the two drugs, with the CI values scattered along the additivity line
(Fig 3), with some indication for synergism only for low concentrations of verapamil in the
W2 strain (S2 Text). The synergism verapamil+ivermectin could be explained by different
hypothesis: i) verapamil may target a transporter that is not drug-specific, but that is responsi-
ble for the detoxification of many different drugs with no similarity in structure and site of
action; ii) verapamil may target multiple transporters each specific for a different class of
drugs; iii) verapamil may act on transporters or pumps that indirectly alter the susceptibility of
Plasmodium to drugs (as proposed by Martiney et al. [44]).
On the other side, in the 72h assays, the medium was not changed. In addition, the 72h
assays were done on asynchronous forms, while the 96h ones were on synchronized parasites.
two time points are difficult to be compared, but the observations are anyway worth to be com-
mented. The effect on the parasite appears to be immediate, in that the effects recorded at 96h
(i.e. after 24h of drug exposure) were comparable to that recorded at 72h (i.e. after 72h of drug
exposure). In other words, the further two days of incubation, up to the 72h time point, did
not apparently lead to a difference in the efficacy of the drugs on the parasite (i.e. the IC50 val-
ues of the drug alone do not decrease between the two incubation times). The early effect of
the drugs was also observed by Dahl et al. [15] with parasites incubated with doxycycline
alone.
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Conclusions
Malaria impact on human health and quality of life has been reduced greatly during the last
century, but its complete eradication is still far from being achieved. Inadequate funding [1,
45], climate changes [46, 47], resistance of malaria vectors towards the most commonly used
classes of insecticides [4, 5], and the continuous emergence of parasite resistance towards anti-
malarial drugs [6, 48], are all factors that might be responsible for the recent increase in
malaria incidence. These conditions, plus the ever-growing difficulty in the development of
new drugs with an antimalarial effect, point to the need to develop novel strategies to fight this
severe disease.
In this study, compounds that are already used in pharmacological therapy, in some cases
already known for their antimalarial potential, have been tested, alone or in combination, with
the purpose to contribute to the uncovering of novel potential combined treatments, as well as
of possible negative drug interactions. The study provided novel results, on the tested drug
combinations, with evidence for drug partners that act synergistically against the parasite
(verapamil plus doxycycline in the CQ resistant strain), and partners that act in an antagonistic
way, such as ivermectin plus doxycycline. This last result is relevant to the issue of mass iver-
mectin administration for onchocerciasis control, in regions where also malaria is endemic
[30]. Considering the possibility that ivermectin and doxycycline are co-administered to the
same patients, the antagonistic effects here recorded are worth of further investigations. On
the other hand, since ivermectin has been shown to interfere with the normal life cycle of P.
falciparum, inhibiting sporogony in the mosquito, influencing schizogony in the liver, and
damaging both asexual and sexual stages in the blood of the host [25, 38], the search for mole-
cules acting synergistically with this drug is also worth of further efforts. As for the verapamil
plus doxycycline combination, the toxicity of verapamil excludes the possibility of exploiting
this molecule as a partner drug in malaria control. However, the synergistic effect of this drug
combination is coherent with the known mechanism of action of verapamil, as an inhibitor of
ABC transporter efflux pumps. Therefore, more specific, or less toxic, efflux pump inhibitors
could be investigated, and a better understanding of the mechanism of detoxification towards
doxycycline could allow future development of novel partner drugs for this antibiotic. Unfor-
tunately, the third-generation ABC transporter inhibitor here tested, elacridar, did not display
any synergistic effect with doxycycline, rather the effect was antagonistic. These discordant
results highlight the complexity of the system: the interplay between drug molecules and their
putative targets, such as the transporters on organelles and on the different host and parasite
membranes, is complex and poorly understood [49, 50]. Therefore, the results here presented,
in term of synergism, additivity or antagonism, highlight issues that are worth of further inves-
tigations, but the translation to clinical application is far, and will obviously require in vivo
studies.
Supporting information
S1 Table. IC50 values of the drugs against the two parasite strains at 72h and 96h. Data are
expressed as IC50 ± SE of each drug alone on P. falciparum chloroquine-sensitive (D10) or
chloroquine-resistant (W2) strains after 72h or 96h bioassays using the pLDH method. The
results are the mean of at least three independent experiments in duplicate. Chloroquine used
as control showed IC50 values of ~19 nM against D10 or ~440 nM against W2.
DOX = doxycycline; IVM = Ivermectin; VPL = Verapamil; ELC = Elacridar.
(DOCX)
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S1 Text. Data used to build Figs 2 and 3 (Fa-CI plot) plus the concentration of drugs in the
combined treatments. Combination index (CI) values were calculated using the equation:
CI = CA,x/ICx,A + CB,x/ICx,B where ICx,A and Cx,B are the concentrations of drug A and drug B
used as a single agent to produce a given effect x and CA,x and CB,x are the concentrations of
drug A and drug B in the combination to produce that same effect. Function of effect level (fa)
represent the mortality induced by the combination of drugs at the selected combination
(where 1 indicates 100% mortality. The values have been obtained from three independent
replicas. Ivermectin (IVM); doxycycline (DOX); Elacridar (ELC); Verapamil (VPL). Drugs
concentration are reported as μM.
(DOCX)
S2 Text. Analyses for the anti-P. falciparum activity of drug combinations with an incuba-
tion time of 72h on asynchronous cultures of D10 or W2 strains, or 96h on synchronized
cultures of D10 or W2 strains. Synergism, additivity or antagonism were classified on the
basis of the Combination Index (CI) values and represented using the recommended symbols
in Chou et al. (2005): CI value <0.1 very strong synergism (+++++), 0.1–0.3 strong synergism
(++++), 0.3–0.7 synergism (+++), 0.7–0.85 moderate synergism (++), 0.85–0.90 slight syner-
gism (+), 0.90–1.10 nearly additive (±), 1.1–1.20 slight antagonism (-), 1.20–1.45 moderate
antagonism (- -), 1.45–3.3 antagonism (- - -), and>3.3 strong antagonism (- - - -), very strong
antagonism (- - - - -) (Source: Compusyn and Calcusyn manual). Ivermectin (IVM); doxycy-
cline (DOX); Elacridar (ELC); Verapamil (VPL).
(DOCX)
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